Drug reference
peficitinib
Pan-JAK inhibitor (JAK1, JAK2, JAK3, and TYK2; modest selectivity for JAK3) · Immunosuppressant
Pan-JAK inhibitor (JAK1, JAK2, JAK3, and TYK2; modest selectivity for JAK3)Immunosuppressant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Not yet extracted
Indications
rheumatoid arthritis (approved in japan and korea)
Contraindications
- nonuse during breastfeeding
- concurrent use of live vaccines
Side effects
Common
thrombocytopeniaanemianeutropeniaincreased risk of infections (upper respiratory, sinus, common cold, hepatitis c virus)increased risk of infections (herpes zoster virus, others)
Serious
- increased risk of serious bacterial, fungal, viral, and opportunistic infections leading to hospitalization or death
- higher rate of all-cause mortality, including sudden cardiovascular death
- higher rate of certain cancers
- higher rate of thrombosis, cardiovascular death, myocardial infarction, and stroke
Related guidelines
Ask House about peficitinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team